Vigil Neuroscience reports positive interim data from phase 2 of their clinical trial evaluating treatment (VGL101) for ALSP and critical insights gained from their natural history study.
– Treatment (Iluzanebart) demonstrated favorable safety and tolerability
– Directionally supportive changes in individual patients at 6 months on MRI and NfL biomarkers
– Natural History Study continued to provide critical insights on MRI and NfL biomarkers
– Company expects to report Phase 2 IGNITE results from patients in third quarter of 2024
To read the press release: Vigil Neuro Update